SinoMab BioScience Ltd represents a strong commitment to delivering innovative biopharmaceutical solutions. The company values scientific excellence, dedication to patients, and respect for employees. With a mission to improve global health, SinoMab is driven by a corporate philosophy of integrity and collaboration. By leveraging cutting-edge research and development capabilities, SinoMab strives to discover breakthrough therapies for unmet medical needs. With a focus on quality and safety, SinoMab BioScience Ltd aims to create value for patients, shareholders, and the healthcare community.

SinoMab BioScience Ltd is primarily present in Hong Kong and Mainland China.

SinoMab BioScience Ltd has achieved several significant milestones in its journey. Firstly, the company successfully developed and commercialized multiple monoclonal antibody drugs, leading to notable advancements in the field of targeted therapeutics. Additionally, SinoMab BioScience Ltd has forged strategic partnerships with renowned pharmaceutical companies, expanding its global presence and fostering collaboration for further growth. The company's dedication to research and innovation has resulted in the successful development of novel antibody therapeutics, addressing critical unmet medical needs. SinoMab BioScience Ltd's relentless pursuit of excellence has earned it a reputation as a leader in the biopharmaceutical industry, with its groundbreaking discoveries and commitment to improving patient outcomes.

SinoMab BioScience Ltd is a leading biotechnology company specializing in antibody research and development. Established in 2001, the company has rapidly grown to become a renowned player in the pharmaceutical industry. With its headquarters in Hong Kong, SinoMab has successfully expanded its operations worldwide, focusing on the discovery and production of innovative monoclonal antibodies for therapeutic treatments. By leveraging cutting-edge technologies and strategic partnerships, SinoMab has built a robust pipeline of potential drugs, targeting various diseases including cancer, inflammation, and autoimmune disorders. With a strong commitment to delivering high-quality and effective treatment options, SinoMab BioScience Ltd continues to make significant contributions to the field of biomedicine.

The main competitors of SinoMab BioScience Ltd in the market include companies such as Johnson & Johnson, Roche Holding AG, Pfizer Inc., and Novartis AG.

SinoMab BioScience Ltd is primarily active in the biotechnology and pharmaceutical industries.

The business model of SinoMab BioScience Ltd is focused on the development and commercialization of innovative monoclonal antibody therapeutics. The company specializes in the research and development of novel biotherapeutics for the treatment of various diseases, including cancers and autoimmune disorders. SinoMab BioScience Ltd operates through a combination of in-house research and collaboration with academic institutions and global pharmaceutical companies. With a strong emphasis on quality and scientific excellence, the company aims to bring effective and safe therapeutic solutions to patients worldwide.

Pašreizējais KGV SinoMab BioScience nevar tikt aprēķināts.

KUV šobrīd SinoMab BioScience nevar aprēķināt.

AlleAktien kvalitātes vērtējums SinoMab BioScience ir 2/10.

Pašreiz nevar aprēķināt apgrozījumu SinoMab BioScience.

Pašlaik peļņa SinoMab BioScience nevar tikt aprēķināta.

SinoMab BioScience Ltd is a biopharmaceutical company based in Hong Kong. The company aims to develop innovative therapies and therapeutics to meet the needs of patients worldwide. SinoMab BioScience operates an integrated business model consisting of three sectors: research and development, manufacturing, and distribution of biopharmaceutical products. The company conducts intensive research and development to bring novel therapies and drugs to the market. They strive to find groundbreaking technologies and therapeutic solutions to fulfill unmet patient needs. SinoMab BioScience produces its biopharmaceutical products in accordance with international Good Manufacturing Practice (GMP) standards to ensure high product quality. The company distributes its products in China and international markets, with strategic partnership support for marketing. Currently, SinoMab BioScience offers four main products, including IBI303, IBI301, SMC-110101, and Leukotuximab, which are used for the treatment of various conditions such as lung cancer, solid tumors, macular degeneration, and acute lymphoblastic leukemia. In summary, SinoMab BioScience operates an integrated business model and offers innovative biopharmaceutical products, aiming to fulfill unmet patient needs through intensive research and development. Through strategic partnerships and international presence, the company is able to distribute its products worldwide, making a positive impact on global patient health.

SinoMab BioScience izmaksā dividendes 0 CNY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt SinoMab BioScience vai uzņēmums nedod dividendes.

SinoMab BioScience ISIN ir HK0000544194.

SinoMab BioScience simbols ir 3681.HK.

Pēdējo 12 mēnešu laikā SinoMab BioScience maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos SinoMab BioScience plāno maksāt dividendes 0 CNY apmērā.

SinoMab BioScience pašreizējā dividendu rentabilitāte ir .

SinoMab BioScience maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

SinoMab BioScience pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CNY. Tas atbilst dividendes ražībai 0 %.

SinoMab BioScience tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu SinoMab BioScience apmērā 0 CNY, kas tika izmaksāta 10.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 10.08.2024..

Pēdējās dividendes izmaksa notika 10.08.2024..

Gadā 2023, SinoMab BioScience izmaksāja 0 CNY dividendes.

SinoMab BioScience dividendes tiek izmaksātas CNY.